HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Name: HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Published: 2023
License: Public Domain

Princess Maxima Center for Pediatric Oncology · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

relapse

acute lymphoblastic leukemia, in relapse, lymphoblastic lymphoma (precursor b-lymphoblastic lymphoma/leukaemia) recurrent, lymphoblastic lymphoma (precursor t-lymphoblastic lymphoma/leukaemia) recurrent, lymphoblastic lymphoma (precursor b-lymphoblastic lymphoma/leukaemia) refractory, lymphoblastic lymphoma (precursor t-lymphoblastic lymphoma/leukaemia) refractory, acute lymphoblastic leukemia, lymphoblastic lymphoma, epigentic approach, decitabine, navitoclax, venetoclax, relapse

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 837980
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.